Prevention of recurrences of erosive reflux esophagitis: A cost- effectiveness analysis of maintenance proton pump inhibition

American Journal of Medicine

Volumn 102, Issue 1, 1997, Pages 78-88

  Harris, Ryan A ^a,b   Kuppermann, Miriam ^a,b   Richter, Joel E ^c  

^a Technology Assessment Group   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; PROTON PUMP INHIBITOR;

ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; ESOPHAGOSCOPY; HEALTH CARE COST; HUMAN; MAINTENANCE THERAPY; MEDICAL DECISION MAKING; MODEL; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; REFLUX ESOPHAGITIS;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; COST-BENEFIT ANALYSIS; ESOPHAGITIS, PEPTIC; HUMANS; OMEPRAZOLE; PROTON PUMPS; QUALITY OF LIFE; RECURRENCE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 0031057513     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(96)00301-4     Document Type: Article

References (49)

1. Kahrilas PJ, Hogan WJ. Gastroesophageal reflux disease. In: Sleisenger MH, Fordtran JS, eds. Gastrointestinal Disease: Pathophysiology, Diagnosis, Management. 5th ed. Philadelphia: WB Saunders; 1993:378-401.
2. McDougall NI, Johnston BT, Kee F, et al. Natural history of reflux esophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life. Gut. 1996; 38:481-486.
3. Richter JE. Surgery for reflux disease-reflections of a gastroenterologist. NEJM. 1992;326:825-827.
4. Johnson DA. Medical therapy for gastroesophageal reflux disease. Am J Med. 1992;92:88S-97S.
5. Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology. 1988;95:903-912.
6. Sontag SJ. The medical management of reflux esophagitis. Role of antacids and acid inhibition. Gastroenterol Clin North Am. 1990;19:683-712.
7. Robinson M, Decktor DL, Maton PN, et al. Omeprazole is superior to ranitidine plus metoclopramide in the short-term treatment of erosive oesophagitis. Aliment Pharmacol Ther. 1993;7(1):67-73.
8. Maton PN. Omeprazole. NEJM. 1991;324:965-975.
9. Lundell L, Backman L, Ekstrom P, et al. Omeprazole or high-dose ranitidine in the treatment of patients with reflux oesophagitis not responding to 'standard doses' of H2-receptor antagonists. Aliment Pharmacol Ther. 1990;4:145-155.
10. Sontag SJ, Hirschowitz BI, Holt S, et al. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the US multicenter study. Gastroenterology. 1992;102:109-118.
11. Klinkenberg-Knol EC, Jansen JM, Festen HP, et al. Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. Lancet. 1987;8529:349-351.
12. Havelund T, Laursen LS, Skoubo-Kristensen E, et al. Omeprazole and ranitidine in treatment of reflux oesophagitis: double blind comparative trial. BMJ. 1988;296:89-92.
13. Vantrappen G, Rutgeerts L, Schurmans P, Coenegrachts J-L. Omeprazole (40 mg) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitis. Dig Dis Sci. 1988;33:523-529.
14. Zeitoun P, Desjars de Keranrou N, Isal JP. Omeprazole versus ranitidine in erosive oesophagitis. Lancet. 1987;8559:621-622.
15. Bate CM, Keeling PW, O'Morain C, et al. Comparison of omeprazole and cimetidine in reflux oesophagitis: symptomatic, endoscopic, and histological evaluations. Gut. 1990;31:968-972.
16. Sandmark S, Carlsson R, Fausa O, Lundell L. Omeprazole or ranitidine in the treatment of reflux esophagitis. Results of a double-blind, randomized, Scandinavian multicenter study. Scand J Gastroenterol. 1988;23:625-632.
17. Lanza F, Goff J, Scowcroft C, et al. Double-blind comparison of lansoprazole, ranitidine, and placebo in the treatment of acute duodenal ulcer. Lansoprazole Study Group. Am J Gastroenterol. 1994;89(8):191-200.
18. Feldman M, Harford WV, Fisher RS, et al, and the Lansoprazole Study Group. Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+/K(+)-ATPase inhibitor: a controlled, double-blind study. Am J Gastroenterol. 1993;88(8):1212-1217.
19. Robinson M, Sahba B, Avner D, et al. A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Aliment Pharmacol Ther. 1995;9:25-31.
20. Pope CE II. Acid-reflux disorders. NEJM. 1994;331:656-660.
21. Klinkenberg-Knol EC, Festen HP, Jansen JB, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med. 1994;121:161-167.
22. Lundell L, Backman L, Ekstrom P, et al. Prevention of relapse of reflux esophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine. Scand J Gastroenterol. 1991;26:248-256.
23. Fiasse R, Druez P, Coppens JP, et al. Omeprazole in the treatment of patients with severe reflux oesophagitis not responding to H2-receptor antagonists and ineligible for surgery. Acta Gastroenterol Belg. 1990;53:573-584.
24. Dent J, Yeomans ND, Mackinnon M, et al. Omeprazole versus ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut. 1994;35:590-598.
25. Hallerback B, Unge P, Carling L, et al. Omeprazole or ranitidine in long-term treatment of reflux esophagitis. The Scandinavian Clinics for United Research Group. Gastroenterology. 1994;107:1305-1311.
26. Robinson MG, Lanza F, Avner D. Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1996;24:859-867.
27. Sontag SJ, Kogut DG, Fleischmann R, et al. Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. Am J Gastroenterol. 1996;91:1758-1765.
28. Fennerty MB, Castell D, Fendrick AM, et al. The diagnosis and treatment of gastroesophageal reflux disease in a managed care environment: Suggested disease management guidelines. Arch Intern Med. 1996;156:477-484.
29. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making. 1983;3:419-458.
30. Dalkey NC. The Delphi Method: An Experimental Study of Group Opinion. Santa Monica, Calif: Rand Corporation (RM5888-PR); 1969:1-88.
31. 1995 Redbook Update.. Montvale, NJ: Medical Economics; 1995;14(6).
32. 1995 National Limitations - Clinical Lab. Washington, DC: US Department of Health and Human Services, Medicare; 1995
33. HealthCare Consultants of America, Inc. 1994 Physicians Fee & Coding Guide. Augusta, Ga: HealthCare Consultants of America; 1994.
34. Government Procurement Prices for Drugs. Washington, DC: US Department of Veterans Affairs; 1995.
35. Finkler SA. The distinction between cost and charges. Ann Intern Med. 1982;96:102-109.
36. Weinstein MC. Principles of cost-effective resource allocation in health care organizations. Int J Technol Assess Health Care. 1990;6:93-103.
37. Drummond M, Torrance G, Mason J. Cost-effectiveness league tables: more harm than good? Soc Sci Med. 1993;37:33-40.
38. Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study. Initial catalog of health state quality factors. Med Decis Making. 1993;13:89-102.
39. Behar J, Sheahan DG, Biancani P, et al. Medical and surgical management of reflux esophagitis: a 38-month report on a prospective clinical trial. NEJM. 1975;293:263-268.
40. Fleiss JL. Statistical Methods for Rates and Proportions. 2nd ed. New York: Wiley and Sons; 1981.
41. Schmitt CM, Brazer SR, Bittner HB, Pappas TN. Outcomes and health-related quality of life (HRQL) after Nissen fundoplication (NF). Gastroenterology. 80:1498.
42. Seabrook M, Holt S, Gilrane T. Barrett's esophagus: observations on diagnosis and management. South Med J. 1992;85:280-288.
43. Lindberg G. Omeprazole vs. ranitidine in reflux oesophagitis in Sweden. Pharmacoeconomics. 1994;5(suppl 3):27-34.
44. Hillman AL, Bloom BS, Fendrick AM, Schwartz JS. Cost and quality effects of alternative treatments for persistent gastroesophageal reflux disease. Arch Intern Med. 1992;152:1467-1472.
45. Bloom BS. Economic evaluation of treatment of gastroesophageal reflux disease in the United States. Pharmacoeconomics. 1994;5(suppl 3):56-59.
46. Bate CM, Richardson PD. A one year model for the cost effectiveness of treating reflux esophagitis. Br J Med Econ. 1992;2:5-11.
47. Stålhammar NO. Assessing the cost effectiveness of medical treatments in acid-related diseases. Scand J Gastroenterol. 1993;199:8-13.
48. Bass EB, Steinberg EP, Pitt HA, et al. Comparison of the rating scale and the standard gamble in measuring patient preferences for outcomes of gallstone disease. Med Decis Making. 1994;14:307-314.
49. Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA. 1995;274:1839-1845.